Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL. Edson-Heredia E, et al. Among authors: leonardi cl. J Eur Acad Dermatol Venereol. 2016 May;30(5):864-5. doi: 10.1111/jdv.13032. Epub 2015 Mar 13. J Eur Acad Dermatol Venereol. 2016. PMID: 25773781 Clinical Trial. No abstract available.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Leonardi CL, et al. Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4. Lancet. 2008. PMID: 18486739 Clinical Trial.
New and emerging therapies in psoriasis.
Leonardi CL, Gordon KB. Leonardi CL, et al. Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S37-41. doi: 10.12788/j.sder.0066. Semin Cutan Med Surg. 2014. PMID: 24979544
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Papp K, et al. Among authors: leonardi cl. J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. J Am Acad Dermatol. 2015. PMID: 26089047 Free article. Clinical Trial.
120 results